ROSETTA CRC-203 is a randomized, blinded phase 2/3 study evaluating pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in patients with previously untreated, unresectable or metastatic colorectal cancer. The primary objective is to compare the efficacy of the two treatment regimens. Eligible participants are adults with no prior systemic therapy for advanced disease. Participants are randomized to receive one of the two treatment combinations.
ROSETTA CRC-203 is a clinical study investigating a new treatment for colorectal cancer that cannot be surgically removed or has spread to other parts of the body. It compares a new drug called pumitamig given together with chemotherapy to a standard treatment consisting of bevacizumab plus chemotherapy. The goal of the study is to determine which treatment is more effective. Adults who have not received prior treatment for their advanced disease can take part. Participants are randomly assigned to one of the two treatment groups. The study is blinded, meaning that certain treatment details are not disclosed.
